Back

Prognostic impact of secondary prevention medical therapy in patients with Takotsubo cardiomyopathy: a Bayesian network meta-analysis

2 September 2024 (15:00 - 15:40)
Organised by: Logo
Congress Presentation Part of: Takotsubo cardiomyopathy and acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ammar Zaka

Gold Coast University Hospital, Southport (Australia)

5 More presentations in this session

Presentation thumbnail
Cardiac autonomic dysfunction in Takotsubo cardiomyopathy: an observational study
Doctor F. Hofer (Innsbruck, AT)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and outcomes of patients with takotsubo syndrome and dynamic left ventricular outflow tract obstruction
Doctor D. Di Vece (Greifswald, DE)
Abstract Slides Video
Presentation thumbnail
A personalized, 3D printed, polymeric elastic support device for the prevention of post-MI cardiac remodeling
Doctor D. Nachman (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Guideline-directed medical therapy titration for heart failure with ischaemic aetiology and its effect on cardiac remodelling and cardiovascular mortality-from a real world perspective
Doctor J. Bonini (Ferrara, IT)
Abstract Slides Video
Presentation thumbnail
Utility of venoarterial extracorporeal membrane oxygenation in patients with acute myocardial infarction complicated by cardiogenic shock
Doctor S. Gupta (Stony Brook, US)
Abstract Slides Video

Access the full session

Session thumbnail
Takotsubo cardiomyopathy and acute coronary syndromes

The Event

Event poster

ESC Congress 2024

2 September 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Use of beta-blockers and in-hospital mortality in patients with Takotsubo cardiomyopathy - a systematic review and meta-analysis
thumbnail
Congress Presentation
Treatment of acute, uncomplicated Takotsubo cardiomyopathy: if, what, and for how long?
thumbnail
Congress Presentation
Cardiovascular and non-cardiovascular prescribing and mortality after takotsubo

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources